CORONA Remedies Limited, a leading India-focused branded pharmaceutical company, announced robust unaudited financial results for the second quarter (Q2) and half year (H1) of FY26.
The consolidated revenue from operations stood at ₹361.13 crore for Q2FY26 and ₹707.67 crore for H1FY26, reflecting year-on-year (YoY) growth of 15.1% and 17.0%, respectively. Profit after tax (PAT) rose to ₹52.32 crore for Q2 and ₹98.52 crore for H1, marking 21.8% and 35.1% YoY growth.
Key Financial Highlights – Q2 & H1 FY26
| Particulars | Q2FY26 (₹ Cr.) | H1FY26 (₹ Cr.) |
|---|---|---|
| Revenue from Operations | 361.13 | 707.67 |
| Gross Profit | 292.48 | 573.24 |
| EBITDA | 78.47 | 148.25 |
| EBITDA Margin | 21.7% | 20.9% |
| PAT | 52.32 | 98.52 |
| PAT Margin | 14.5% | 13.9% |
H1 FY26 Metrics:
- RoE (Annualized): 31.1%
- RoCE (Annualized): 49.7%
- OCF to EBITDA: 76.5%
- Net Working Capital Days: 23
CORONA Remedies operates in women’s healthcare, cardio-diabetes, pain management, urology, and other therapeutic segments, and manufactures products at WHO-GMP/EU GMP-certified facilities. The company has two DSIR-approved R&D centres with over 100 scientists, and employs more than 4,500 professionals.
Earnings Call
CORONA Remedies will host an earnings call on 5 January 2026 at 12:00 PM IST to discuss Q2FY26 and H1FY26 results. Participants can join via the dial-in numbers or Diamond Pass link provided by the company.
Outlook
The company cited strong execution, expanded brand portfolio, and increased focus on specialist prescriptions as key drivers behind the growth. CORONA’s leadership emphasized that its consistent performance strengthens the foundation for long-term sustainable growth.
For more information, visit www.coronaremedies.com.
Disclaimer: Certain statements in this article are forward-looking and based on management assumptions. Actual results may differ due to risks and uncertainties. This is not an offer to buy or sell shares, and readers should conduct their own research or consult a financial advisor before investing.
